Else Nutrition Reports 2025 First Quarter Financial Results and Provides Business Update
Else Nutrition (OTCQX: BABYF) reported its Q1 2025 financial results, maintaining revenue at $2.1 million year-over-year while significantly improving operational efficiency. The company achieved a notable reduction in operating expenses by 48% to $2.2 million and increased gross profit margin to 25% from 8% in Q1 2024.
Key strategic initiatives include shifting powder formula manufacturing to Europe to reduce production costs and improve margins. The company is also optimizing its retail distribution model and pursuing regulatory advancement through Operation Stork Speed and the FY2026 Agriculture Appropriations Bill, which could streamline FDA approval pathways for plant-based infant nutrition alternatives.
The company ended Q1 2025 with a cash balance of $0.2 million, including restricted cash, and is exploring strategic collaborations to accelerate growth.
Else Nutrition (OTCQX: BABYF) ha comunicato i risultati finanziari del primo trimestre 2025, confermando ricavi invariati a $2,1 milioni su base annua e migliorando in modo significativo l’efficienza operativa. L’azienda ha ridotto le spese operative del 48% portandole a $2,2 milioni e ha aumentato il margine lordo al 25% rispetto all’8% del primo trimestre 2024.
Tra le iniziative strategiche principali c’è lo spostamento della produzione di formule in polvere in Europa per ridurre i costi produttivi e migliorare i margini. La società sta anche ottimizzando il modello di distribuzione al dettaglio e prosegue nelle attività regolatorie attraverso Operation Stork Speed e il FY2026 Agriculture Appropriations Bill, che potrebbero agevolare i percorsi di approvazione FDA per alternative vegetali alla nutrizione infantile.
Al termine del Q1 2025 la posizione di cassa era di $0,2 milioni, comprensivi di cash vincolato, e la società sta valutando collaborazioni strategiche per accelerare la crescita.
Else Nutrition (OTCQX: BABYF) informó sus resultados financieros del primer trimestre de 2025, manteniendo los ingresos en $2.1 millones interanuales y mejorando de forma notable la eficiencia operativa. La compañía redujo los gastos operativos en un 48% hasta $2.2 millones y elevó el margen bruto al 25% desde el 8% en el Q1 de 2024.
Las iniciativas estratégicas clave incluyen trasladar la fabricación de la fórmula en polvo a Europa para reducir costos de producción y mejorar márgenes. Además, la empresa está optimizando su modelo de distribución minorista y avanzando en asuntos regulatorios mediante Operation Stork Speed y el FY2026 Agriculture Appropriations Bill, que podrían agilizar las vías de aprobación de la FDA para alternativas vegetales en nutrición infantil.
Al cierre del Q1 2025, la compañía contaba con un saldo de efectivo de $0.2 millones, incluido efectivo restringido, y está explorando colaboraciones estratégicas para acelerar el crecimiento.
Else Nutrition (OTCQX: BABYF)는 2025 회계연도 1분기 실적을 발표했으며, 매출은 전년 동기 대비 $2.1백만으로 유지되는 가운데 영업 효율성은 크게 개선되었습니다. 회사는 영업비용을 48% 줄여 $2.2백만으로 낮췄고, 매출총이익률은 2024년 1분기의 8%에서 25%로 상승했습니다.
주요 전략적 이니셔티브로는 생산비 절감과 마진 개선을 위해 분말 제형 제조를 유럽으로 이전하는 계획이 포함됩니다. 또한 소매 유통 모델을 최적화하고 Operation Stork Speed 및 FY2026 Agriculture Appropriations Bill을 통한 규제 진전을 추진하여 식물성 영유아 영양 대체품에 대한 FDA 승인 절차를 간소화하려 하고 있습니다.
2025년 1분기 말 현금 잔액은 제한된 현금을 포함해 $0.2백만이었으며, 성장을 가속화하기 위한 전략적 협력 방안을 모색하고 있습니다.
Else Nutrition (OTCQX: BABYF) a publié ses résultats du premier trimestre 2025, maintenant un chiffre d’affaires de $2,1 millions en glissement annuel tout en améliorant significativement son efficacité opérationnelle. La société a réduit ses charges d’exploitation de 48% à $2,2 millions et a porté la marge brute à 25% contre 8% au T1 2024.
Parmi les initiatives stratégiques clés figure le transfert de la fabrication des formules en poudre vers l’Europe afin de réduire les coûts de production et d’améliorer les marges. L’entreprise optimise également son modèle de distribution au détail et poursuit des avancées réglementaires via Operation Stork Speed et le FY2026 Agriculture Appropriations Bill, susceptibles de faciliter les voies d’homologation FDA pour des alternatives végétales à la nutrition infantile.
Au terme du T1 2025, la société disposait d’un solde de trésorerie de $0,2 millions, y compris des liquidités restreintes, et explore des collaborations stratégiques pour accélérer sa croissance.
Else Nutrition (OTCQX: BABYF) meldete seine Finanzergebnisse für das erste Quartal 2025 und hielt den Umsatz mit $2,1 Millionen im Jahresvergleich stabil, während die operative Effizienz deutlich verbessert wurde. Das Unternehmen senkte die operativen Aufwendungen um 48% auf $2,2 Millionen und steigerte die Bruttomarge auf 25% gegenüber 8% im Q1 2024.
Zu den zentralen strategischen Maßnahmen gehört die Verlagerung der Pulverformel-Produktion nach Europa, um Produktionskosten zu senken und die Margen zu verbessern. Zudem optimiert das Unternehmen sein Einzelhandelsvertriebsmodell und treibt regulatorische Fortschritte durch Operation Stork Speed und den FY2026 Agriculture Appropriations Bill voran, was Zulassungswege der FDA für pflanzenbasierte Säuglingsnahrung erleichtern könnte.
Zum Ende des Q1 2025 verfügte das Unternehmen über einen Kassenbestand von $0,2 Millionen, einschließlich gebundenen Mitteln, und prüft strategische Kooperationen zur Beschleunigung des Wachstums.
- Significant improvement in gross profit margin to 25% from 8% year-over-year
- Operating expenses reduced by 48% to $2.2 million
- Strategic shift to European manufacturing to reduce production costs
- Potential regulatory pathway improvements through Operation Stork Speed initiative
- Stagnant revenue growth with Q1 2025 revenue flat at $2.1 million year-over-year
- Low cash balance of $0.2 million as of March 31, 2025
- Continued regulatory hurdles for infant formula approval
Conference call to be held today at 10:00 AM Eastern Time
2025 First Quarter Financial Results
All figures are in CAD unless otherwise indicated.
- Revenue for the first quarter of 2025 was
$2.1 million - Operating expenses for the first quarter of 2025 were
$2.2 million 48% compared to$4.2 million - Gross profit for the first quarter of 2025 increased to
$0.5 million $0.18 million - Gross profit margin for the first quarter of 2025 increased significantly to
25% , compared to8% in the first quarter of 2024. - Cash balance as of March 31, 2025, was
$0.2 million
"As we entered 2025, we continued reshaping Else Nutrition—implementing strategic changes essential to long-term success," commented Hamutal Yitzhak, CEO & Co-Founder of Else Nutrition. "Despite the lingering headwinds from 2024, we held revenue steady while significantly reducing operating expenses and driving a sharp improvement in gross profit. We are now operating with more discipline, sharper focus, and growing confidence in our direction. We've made tough but necessary decisions to realign our structure and eliminate inefficiencies, allowing us to protect core capabilities and build a more resilient foundation."
"Operationally, a major milestone is our planned shift toward manufacturing powder formulas in
"On the regulatory front, we remain deeply committed to advancing access to plant-based infant nutrition. The launch of Operation Stork Speed and the advancement of the FY2026 Agriculture Appropriations Bill mark pivotal progress in modernizing
"The remainder of 2025 will be an important period as we continue to implement the changes necessary to strengthen the business. We are focused on deepening our retail partnerships, expanding our global manufacturing capabilities, and driving growth across our core product categories. We are also exploring select strategic collaborations that align with our mission and can accelerate our path to scale. As we continue executing our transformation, our commitment remains clear: to deliver clean, innovative nutrition solutions to more families around the world while building a stronger, more agile business for the long term."
Conference Call
Else Nutrition management plans to host a business update conference call today at 10:00 a.m. Eastern Time to discuss the Company's financial results for the first quarter of 2025 ended March 31, 2025, as well as the Company's corporate progress and other developments.
The conference call will be available via telephone by dialing toll free 1-877-407-9219 for
A webcast replay will be available on the Investor Relations section of the Company's website (https://investors.elsenutrition.com/), through August 21, 2026. A telephone replay of the call will be available approximately three hours following the call, through September 3, 2025, and can be accessed by dialing 1-877-660-6853 for
To delve deeper into Else Nutrition's offerings and its revolutionary approach to kids' nutrition, visit www.elsenutrition.com
About Else Nutrition Holdings Inc.
Else Nutrition Holdings Inc. (TSX: BABY, OTCQX: BABYF, FSE: 0YL) is a food and nutrition company in the international expansion stage focused on developing innovative, clean, and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy formula is a clean-ingredient alternative to dairy-based formulas. Since launching its Plant-Based Complete Nutrition for Toddlers, made of whole foods, almonds, buckwheat, and tapioca, the brand has received thousands of powerful testimonials and reviews from parents, gained national retailer support, and achieved rapid sales growth.
Awards and Recognition:
- "2017 Best Health and Diet Solutions" award at
Milan 's Global Food Innovation Summit - #1 Best Seller on Amazon in the Fall of 2020 in the New Baby & Toddler Formula Category
- "Best Dairy Alternative" Award 2021 at World Plant-Based Expo
- Nexty Award Finalist at Expo West 2022 in the Plant-Based lifestyle category
- During September 2022, Else Super Cereal reached the #1 Best Seller in Baby Cereal across all brands on Amazon
- In May 2024 Else Nutrition's Ready-to-Drink Kids Vanilla Shake Named Among the Best in Family-Friendly Products by the Prestigious Mom's Choice Awards®
TSX
Neither the TSX nor its regulation services provider (as that term is defined in the policies of the TSX) accept responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Statements
This press release contains statements that may constitute "forward-looking statements" within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as "will" or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the company's financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs, and assumptions, which are based on management's perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID-19 and that the manufacturing, broker, and supply logistic agreement with the company does not terminate. Actual results may differ from the estimates, beliefs, and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management's expectations only as of the date of this press release. The company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/else-nutrition-reports-2025-first-quarter-financial-results-and-provides-business-update-302535291.html
SOURCE Else Nutrition Holdings Inc.
FAQ
What were Else Nutrition's (BABYF) Q1 2025 financial results?
How much did Else Nutrition (BABYF) reduce its operating expenses in Q1 2025?
What strategic changes is Else Nutrition implementing in 2025?
What was Else Nutrition's cash position at the end of Q1 2025?
How did Else Nutrition's gross profit margin change in Q1 2025?
